HCL | Vitabase

Other Names

(Carboxymethyl)trimethylammonium chloride(Carboxymethyl)trimethylammonium hydrochloride(Trimethylammonio)acetate hydrochloride1-Carboxy-N,N,N-trimethylmethanaminium chlorideAchylinAcide Chlorhydrique de BétaïneAcidinAcidineAcidogenoAcidolAcidol hydrochlorideAcinormAcipepsolAciventral forteAmmonium, (carboxymethyl)trimethyl-, chlorideBetain hydrochlorideBetaine ChlorhydrateBetaine chlorideBétaïne HClBetaine HClBetaine hydrochloric acidBetaine HydrochlorideBetainium chlorideChlorhidrato de BetaínaChlorhydrate de BétaïneChlorhydrate de TriméthylglycineEuacidGlycine Betaine Hydrochloric acidGlycine betaine hydrochlorideGlycocollbetaine hydrochlorideLycine hydrochlorideMethanaminium, 1-carboxy-N,N,N-trimethyl-, chlorideN,N,N-Trimethylglycine hydrochloridePluchineRubrine C hydrochlorideTMGTrimethyl GlycineTrimethylglycineTriméthylglycineTrimethylglycine hydrochloride

Synopsis

Betaine Hydrochloride (HCl): A Comprehensive Reference

1. Identity, Chemical Nature, and Natural Sources

Chemical Identity

Betaine hydrochloride (commonly abbreviated as Betaine HCl or BHCl) is the hydrochloride salt of betaine. Betaine itself is a zwitterionic quaternary ammonium compound also known as trimethylglycine, glycine betaine, lycine, and oxyneurine. It is a methyl derivative of the amino acid glycine with a molecular formula of (CH₃)₃N⁺CH₂COO⁻ and a molecular weight of 117.2, and it has been characterized as a methylamine because of its three chemically reactive methyl groups.

Betaine (trimethylglycine) is a natural product — it is a glycine derivatized by three extra methyl groups. When betaine is combined with hydrochloric acid to form betaine hydrochloride, the result is a compound that readily releases H⁺ in an aqueous environment (approximately 0.65 mmol per 100 mg). This distinguishes betaine HCl sharply from betaine anhydrous (trimethylglycine), and it is important to distinguish between these agents as they have very different chemistry and clinical indications.

The compound is known by numerous synonyms and trade names, including: Acide Chlorhydrique de Bétaïne, Betaine Chlorhydrate, Betaine HCl, Chlorhydrate de Bétaïne, Chlorhydrate de Triméthylglycine, Glycine Betaine Hydrochloric acid, TMG, Trimethyl Glycine, Trimethylglycine, and Trimethylglycine hydrochloride.

Natural Sources of Betaine

Betaine is a stable and harmless natural constituent that exists in plants, animals, and microorganisms. The highest concentrations in food matrices are observed in cereal grains, pseudocereals (especially amaranth and quinoa), cereal products (wholegrain flour, bread, pasta, couscous, and breakfast cereals), some vegetables (spinach and beetroot), and the majority of seashells (mussels, oysters, clams, and scallops).

Rich dietary sources of betaine include seafood, especially marine invertebrates (approximately 1%); wheat germ or bran (approximately 1%); and spinach (approximately 0.7%). Intake of betaine from foods is estimated at 200–400 mg/day.

Betaine is not regarded as an essential nutrient because it may be irreversibly produced in the human body from free choline with the aid of the choline dehydrogenase enzyme; however, the body's natural ability to produce betaine is typically insufficient to meet daily requirements, so consuming betaine through diet is required.

Betaine can be synthesized endogenously through choline metabolism, where choline dehydrogenase oxidizes choline to betaine aldehyde, which is then converted to betaine by betaine aldehyde dehydrogenase in the presence of nicotinamide adenine dinucleotide (NAD⁺).

Commercial Preparation

For secondary industries, betaine can be produced by chemical synthesis or by relatively expensive isolation from sugar beets or byproducts of beet processing. Today, betaine can be supplemented as natural betaine isolated from natural sources, as synthetic anhydrous betaine, or as synthetic betaine HCl.

Betaine HCl is the most common hydrochloric acid-containing supplement and normally comes in tablets or capsules measured in grains or milligrams. One grain of betaine HCl is equal to 65 mg. Because betaine HCl readily donates H⁺ in an aqueous environment, it is essential that betaine HCl supplements are taken in the form of capsules or tablets when ingested.

2. Traditional and Historical Use

Early Commercial and Naturopathic History

Betaine hydrochloride used to be included in over-the-counter (OTC) products as a "stomach acidifier and digestive aid," but a federal law that went into effect in 1993 banned betaine hydrochloride from use in OTC products because there wasn't enough evidence to classify it "generally recognized as safe and effective." Betaine hydrochloride is now available only as a dietary supplement whose purity and strength can vary.

Specifically, US Code of Federal Regulations, Title 21, Section 310.540, which became effective in November 1993, banned the marketing of betaine hydrochloride as a digestive aid. Despite this regulatory action, the United States FDA banned the use of betaine hydrochloride in over-the-counter medicines in 1993, but because the FDA does not regulate supplements, it remains available for use.

A major branch of alternative medicine known as naturopathy has long held that low stomach acid is a widespread problem that interferes with digestion and the absorption of nutrients. The clinical rationale for betaine HCl use in naturopathic traditions rests on the premise that while conventional medical literature routinely suggests that the amount of stomach acid production is more than adequate for the purposes of digestion in healthy subjects, meal-time "functional hypochlorhydria" may be much more common in older subjects, and the rampant use of drugs to suppress acid production increases the frequency of mealtime hypochlorhydria in many subjects.

It is common within the functional and integrative medicine community to recommend supplemental agents to correct inadequate levels of stomach acid, pancreatic enzymes and/or bile acid secretion, as these are considered to greatly contribute to an individual's risk for maldigestion or malabsorption. Routine mealtime "replacement" of one or more of these agents is commonly recommended by such practitioners to improve digestion and absorption.

Bitter-tasting plants or plant extracts (bitters) have been commonly used in many herbal medicinal traditions to promote digestion and/or to relieve digestive complaints, and mechanisms have been studied in in vitro models for the potential role of bitters in acid secretion; however, there is little in the way of systemic research in humans to suggest specific preparations and dosages.

Proposed Uses in Alternative Practice

Betaine HCl has been commonly recommended for a variety of health concerns, including asthma, digestive issues, excess Candida, food allergies, hay fever, lupus, rheumatoid arthritis, and ulcers. The theory behind its use hinges on the belief that low stomach acid may lead to incomplete digestion, potentially resulting in various allergic reactions and digestive problems.

3. Key Constituents and Mechanisms of Action

Primary Active Component: Hydrochloric Acid (HCl)

In the stomach, betaine hydrochloride breaks down into betaine and a strong acid called hydrochloric acid. This dissociation is the principal mechanism underlying betaine HCl's gastrointestinal effects. Betaine HCl readily releases H⁺ in an aqueous environment (approximately 0.65 mmol per 100 mg), providing a direct exogenous source of gastric acid capable of lowering intragastric pH.

Betaine as a Methyl Donor

Once betaine HCl dissociates, the released betaine moiety functions independently as a critical methyl donor in human metabolism. The principal physiologic role of betaine is as an osmolyte and methyl donor (transmethylation). As an osmolyte, betaine protects cells, proteins, and enzymes from environmental stress (e.g., low water, high salinity, or extreme temperature). As a methyl donor, betaine participates in the methionine cycle — primarily in the human liver and kidneys.

Betaine homocysteine methyltransferase (BHMT), a Zn²⁺-dependent thiolmethyltransferase, contributes to the regulation of homocysteine levels, increases in which are considered a risk factor for cardiovascular diseases. Most plasma homocysteine is generated through the liver methionine cycle, in which BHMT metabolizes approximately 25% of this non-protein amino acid.

One pathway of homocysteine remethylation, present in virtually all cells, involves the enzyme methionine synthase (MS), which requires vitamin B12 as a cofactor, and also depends indirectly on folate and other B vitamins. The second pathway is restricted to the liver and kidneys in most mammals and involves betaine-homocysteine methyltransferase (BHMT), requiring trimethylglycine as a methyl donor. During normal physiological conditions, the two pathways contribute equally to removal of homocysteine in the human body.

Osmolytic Role

Betaine acts as an osmotic regulator, protecting cells, proteins and enzymes from environmental stresses, such as high salinity, extreme temperature or shortage of water. Betaine is mainly distributed in the kidneys, liver and brain.

Lipid Metabolism Effects

Inadequate dietary intake of methyl groups leads to hypomethylation in many important pathways, including disturbed hepatic protein (methionine) metabolism as determined by elevated plasma homocysteine concentrations and decreased S-adenosylmethionine concentrations, and inadequate hepatic fat metabolism, which leads to steatosis (fatty accumulation) and subsequent plasma dyslipidemia.

The mechanism by which betaine might increase total serum cholesterol and LDL cholesterol concentration has been proposed to be the increase in synthesis and export of lipids in very low density lipoprotein from the liver into the circulation. Betaine is formed from choline; and so betaine supplementation spares this use of choline so that more is available for phosphatidylcholine biosynthesis in the liver, thereby making more available for very low density lipoprotein formation.

4. Scientific Evidence by Area of Use

4.1 Gastric Acidification / Hypochlorhydria

While betaine HCl supplementation is widely recommended, there is limited published data evaluating the effects of this agent on stomach pH and, subsequently, digestive outcomes.

The most robust human evidence comes from a pharmacological study. A pilot study evaluated the extent and time course of gastric reacidification after a solid oral dosage form of anhydrous betaine HCl in healthy volunteers with pharmacologically induced hypochlorhydria. Six healthy volunteers with baseline normochlorhydria (fasting gastric pH < 4) were enrolled in this single-period study. Hypochlorhydria was induced via 20 mg oral rabeprazole twice daily for four days.

Gastric pH in all subjects fell rapidly from an average pH of 5.2 in the half hour prior to the ingestion of betaine HCl to an average pH of 0.6 thirty minutes after supplementation. While the gastric acidification was rapid, averaging 6.25 minutes to reach pH < 3, the total duration of re-acidification lasted just longer than one hour (average time to rebound to pH > 3 was 73 minutes, rebound to pH > 4 was 77 minutes, though there was a wide inter-individual range [±30 minutes] for rebound).

In healthy volunteers with pharmacologically induced hypochlorhydria, betaine HCl was effective at temporarily lowering gastric pH. The rapid onset and relatively short duration of gastric pH reduction gives betaine HCl the potential to aid the absorption of orally administered weakly basic drugs that exhibit pH-dependent solubility when administered under hypochlorhydric conditions.

Limitations: The functional-medicine use case rests on the Yago mechanism plus older achlorhydria literature. No large modern RCTs have evaluated betaine HCl in patients with symptomatic hypochlorhydria. Effect-size estimates are unavailable. Importantly, recent evidence questions whether age-related gastric secretion decline is as prevalent as commonly assumed. A JAMA study found that true age-related hypochlorhydria is less common than functional-medicine framings suggest.

Evidence strength: Preliminary (small pilot studies only; no randomized controlled trials in naturally hypochlorhydric patients).

4.2 pH-Dependent Drug Absorption Enhancement

Many orally administered, small-molecule, targeted anticancer drugs, such as dasatinib, exhibit pH-dependent solubility and reduced drug exposure when given with acid-reducing agents. Betaine hydrochloride (BHCl) was demonstrated to transiently re-acidify gastric pH in healthy volunteers with drug-induced hypochlorhydria. In a randomized, single-dose, three-way crossover study, healthy volunteers received dasatinib (100 mg) alone, after pretreatment with rabeprazole, and with 1500 mg BHCl after rabeprazole pretreatment, to determine if BHCl can enhance dasatinib absorption in hypochlorhydric conditions.

Rabeprazole (20 mg b.i.d.) significantly reduced dasatinib Cmax and AUC₀-∞ by 92 and 78%, respectively. However, coadministration of BHCl significantly increased dasatinib Cmax and AUC₀-∞ by 15- and 6.7-fold, restoring them to 105 and 121%, respectively, of the control (dasatinib alone). Therefore, BHCl reversed the impact of hypochlorhydria on dasatinib drug exposure and may be an effective strategy to mitigate potential drug-drug interactions for drugs that exhibit pH-dependent solubility and are administered orally under hypochlorhydric conditions.

However, this effect is context-dependent. In a follow-up study evaluating whether betaine HCl supplementation could affect the absorption of a different pH-dependent drug (atazanavir) in healthy subjects (N = 8) in whom hypochlorhydria was induced using a PPI drug (rabeprazole, 20 mg twice daily), the meal was administered at T0 followed by betaine HCl (1500 mg) ten minutes later (T10). In this study, 1500 mg of betaine HCl was not shown to significantly improve the absorption of atazanavir in subjects with PPI-induced achlorhydria given a meal, though betaine HCl supplementation did decrease the gastric pH.

These results occurred in the fasted state in the dasatinib trial, whereas subsequent research by this group suggests that food can alter the re-acidification dynamics.

Evidence strength: Moderate for fasted-state drug absorption enhancement; mixed in fed state. Small crossover trials; needs replication in larger populations.

4.3 Homocysteine Reduction

It is critical to note here that the evidence for homocysteine lowering pertains primarily to betaine (trimethylglycine / betaine anhydrous), not specifically to betaine HCl. Occasionally, betaine (trimethylglycine) is recommended to reduce blood levels of homocysteine, which is associated with heart disease. This form of betaine is different from betaine HCl.

A meta-analysis shows that supplementation of betaine at 4 to 6 g/d significantly lowers plasma homocysteine concentration in healthy adults by 1.23 μmol/L or 11.8% of baseline values.

A 2021 systematic review and meta-analysis found that betaine supplementation had a significant effect on concentrations of betaine (MD: 82.14 μmol/L), total cholesterol (TC) (MD: 14.12 mg/dl), low-density lipoprotein (LDL) (MD: 10.26 mg/dl), and homocysteine (WMD: -1.30 micromol/L, 95% CI: -1.61 to -0.98).

However, the cardiovascular benefit of homocysteine lowering via betaine is complicated by lipid effects: the unfavorable effects on serum lipids with betaine supplementation may undo the favorable homocysteine-lowering effects, as a 5- to 10-mg/dL increase in total serum cholesterol can increase the risk of developing cardiovascular disease by 3% to 6%. Therefore, in patients with normal plasma homocysteine levels, betaine supplementation may have a negligible effect on cardiovascular health.

Betaine is effective in reducing homocysteine levels, particularly in patients with homocystinuria, where twice-daily administration significantly lowers homocysteine. The US FDA approved betaine trimethylglycine (also known by the brand name Cystadane) for the treatment of homocystinuria, a disease caused by abnormally high homocysteine levels at birth. This approval, however, applies specifically to betaine anhydrous, not betaine HCl.

Evidence strength for homocysteine lowering: Moderate-to-strong for betaine anhydrous/TMG (meta-analyses of RCTs); evidence not established separately for betaine HCl.

4.4 Blood Lipids

A meta-analysis was performed on randomized placebo-controlled trials on the effects of betaine supplementation at a daily dose of at least 4 g on blood lipids in adults. Six randomized controlled trials published between 2002 and 2018 were identified; all six studies used adult participants supplemented with at least 4 g/d of betaine for six to twenty-four weeks.

Betaine supplementation at a dose of at least 4 g/day for six to twenty-four weeks moderately increases total cholesterol levels. Betaine supplementation increased blood LDL cholesterol and triacylglycerol concentrations in healthy humans; the adverse effects on blood lipids may undo the potential benefits for cardiovascular health of betaine supplementation through homocysteine lowering.

A significant increase in total and low-density lipoprotein (LDL)-cholesterol concentrations was noted at intakes of 4 g/day of betaine in overweight subjects with metabolic syndrome but not in healthy subjects, nor at intakes of 3 g/day.

Meta-analysis also indicated that betaine supplementation did not affect serum concentrations of triglyceride (TG), high-density lipoprotein (HDL), fasting blood glucose (FBG), or C-reactive protein (CRP).

Evidence strength: Moderate (multiple RCTs and meta-analyses); raises LDL/TC, particularly at ≥4 g/day and in metabolically compromised individuals.

4.5 Digestion, Protein Breakdown, and Nutrient Absorption

Gastric acid is needed for the active absorption of iron, zinc, B complex vitamins, especially B12, and digestion of consumed proteins. Hypochlorhydria may contribute to poor protein digestion, reduced micronutrient absorption, increased risk of dysbiosis, SIBO, or other symptoms associated with functional dyspepsia.

The clinical case for betaine HCl supplementing these processes is illustrated by a published case report. Esophagectomy patients are left with significant anatomical changes to the GI tract, including the cutting of the vagus nerve, which regulates gastric secretions, gastric acid pH, and motility. In a case of a 76-year-old male patient who self-referred for nutritional management of chronic nausea, fatigue, weight loss, and dumping syndrome nine months post-esophagectomy, a physical functional nutritional assessment suggested gastric hypochlorhydria.

A digestive supplement, betaine hydrochloric acid with pepsin (BHClP), was introduced, and the patient ingested 1 capsule containing 500 mg betaine hydrochloride and 23.5 mg pepsin prior to protein-containing meals and reported a substantial decrease in GI symptoms while eating a regular diet. After a few months, the patient discontinued BHClP, and GI symptoms and dumping syndrome returned, leading to a loss of 7.5% of his body weight. The patient reinitiated the supplement and GI symptoms dissipated, and weight was restored. BHClP provided metabolic therapeutic benefit to optimize the patient's oral intake, preventing further complications and malnutrition.

However, there are no controlled studies on betaine HCl and nutrient deficiencies. All claims in that regard are based on patient testimonials (reports). Until there is at least some controlled evidence, it should not be recommended specifically to enhance nutrient absorption.

The rationale is mechanistically sound — low gastric acid impairs mineral bioavailability, and that relationship is well-established. Atrophic gastritis and PPI use are associated with reduced vitamin B12 status. The link between achlorhydria and iron deficiency anemia exists but the evidence is mixed. No controlled trial has shown that betaine HCl reverses B12 or iron deficiency in hypochlorhydric patients.

Evidence strength: Mechanistically plausible; very limited direct clinical evidence (single case reports and anecdotal clinical data; no RCTs in patients with naturally occurring hypochlorhydria).

4.6 Autoimmune Gastritis (Emerging / Investigational)

In autoimmune gastritis, progressive hypochlorhydria reduces pepsin activity, impairs gastric motility, and promotes small intestinal bacterial overgrowth (SIBO), causing dyspeptic symptoms and micronutrient malabsorption. Furthermore, gastric hypoacidity increases N-nitroso compound formation and triggers hypergastrinemia, elevating risks for both gastric cancer and neuroendocrine tumors.

A clinical trial is investigating whether betaine hydrochloride (with pepsin) supplementation can restore gastric acidity and improve clinical outcomes in autoimmune gastritis, evaluating its effects on gastrin levels, gastrointestinal symptoms, exhaled gas markers, anemia parameters, endoscopic atrophy scores, and incidence of gastric complications including hyperplastic polyps, neuroendocrine tumors, and adenocarcinoma.

Evidence strength: Investigational — ongoing clinical trials only; no results available.

5. Body Systems and Health Areas Associated with Betaine HCl

Gastrointestinal system: Gastric acid production, protein digestion, gastric motility, gut microbiome balance, SIBO prevention, management of functional dyspepsia and hypochlorhydria.
Cardiovascular system: Betaine status is a component of an individual's biochemical make-up with ramifications to one-carbon metabolism. Betaine status should be investigated in pathologies related to altered metabolism of homocysteine and folate, including cardiovascular disease, cancer and neural tube defects.
Hepatic (liver) system: Adequate methyl group intake supports hepatic fat metabolism; deficiency leads to steatosis and subsequent plasma dyslipidemia.
Renal system: Betaine is mainly distributed in the kidneys, liver and brain, where it plays an osmolytic role in the renal medulla.
Immune/allergic responses: Betaine HCl may help restore stomach acid levels and improve digestion in individuals with hypochlorhydria, potentially reducing food-allergy reactions by aiding in protein breakdown. Preliminary evidence suggests it may also improve asthma symptoms and reduce allergic reactions by improving stomach acid production. These claims remain unsupported by controlled clinical trials.
Nutritional/metabolic system: Micronutrient absorption (particularly iron, zinc, and vitamin B12), methyl group donation, and one-carbon metabolism.
Pharmacokinetic interactions: Due to its pH-modifying effects, betaine HCl may have a significant impact on the oral bioavailability of drugs that exhibit pH-dependent solubility, including proton pump inhibitors, H2-receptor antagonists, antacids, pentagastrin and betaine HCl itself.

6. Dosage Forms and Dosages Reported in Studies

This supplement is usually taken in pill form, with dosages ranging from 325 to 650 milligrams taken with meals.

When appropriate, some doctors recommend taking one or more tablets or capsules, each 5–10 grains (325–650 mg), with a meal that contains protein. People should not take more than 10 grains (650 mg) of betaine HCl without the recommendation of a physician.

In pharmacokinetic studies: A dose of 1500 mg (~23 grains) was used to quickly acidify gastric pH in achlorhydric subjects in the published UCSF studies, with demonstrated safe use in subjects treated with proton pump inhibitors.

In the dasatinib absorption study: Healthy volunteers received 1500 mg BHCl after rabeprazole pretreatment to determine if BHCl can enhance dasatinib absorption in hypochlorhydric conditions.

In the homocysteine meta-analyses: Supplementation of betaine at 4 to 6 g/d was studied for homocysteine-lowering effects.

In the esophageal cancer case report: The patient ingested 1 capsule containing 500 mg betaine hydrochloride and 23.5 mg pepsin prior to protein-containing meals.

The autoimmune gastritis clinical trial uses: Oral betaine hydrochloride, 2 capsules, 3 times daily.

Regarding meal timing, a published clinical review notes that it is important that betaine HCl be taken with a meal of sufficient size (500 calories or more) containing adequate protein; with smaller meals, less betaine HCl is needed, so a reduced dose may be adequate.

The EFSA safety opinion on betaine as a novel food, addressing betaine generally, concluded that considering 4 g/day of betaine as a reference point and applying an uncertainty factor of 10 to account for interindividual variability, an amount of 400 mg/day of betaine in addition to the background exposure is considered as safe; the Panel considers that the NF is safe to be used at maximum intake of 6 mg/kg bw per day in the target population. This recommendation, from EFSA, pertains to betaine added to food and does not directly address supplemental betaine HCl dosing.

7. Safety Considerations and Drug Interactions

General Tolerability

Betaine hydrochloride is used to increase stomach acid in people with low levels (hypochlorhydria). It seems to be well tolerated, but there is not enough research to know what side effects it may cause. In the UCSF pilot gastric acidification study, betaine HCl was well tolerated by all subjects.

Peptic Ulcer Disease

Betaine hydrochloride can increase stomach acid; there is a concern that the hydrochloric acid produced from betaine hydrochloride might irritate stomach ulcers or keep them from healing. Administration of HCl/pepsin is specifically contraindicated in peptic ulcer disease.

NSAIDs and Corticosteroids

Betaine HCl should not be combined with NSAIDs or corticosteroids. Anti-inflammatory drugs like ibuprofen, aspirin, naproxen, and corticosteroids such as prednisone compromise the stomach's protective mucosal lining. Combining these medications with supplemental acid significantly increases the risk of ulceration and gastrointestinal bleeding.

Antacids and Acid-Suppressing Medications

Betaine hydrochloride increases stomach acid. Antacids are taken to decrease stomach acid. Taking betaine hydrochloride along with antacids might reduce the effects of antacids. Similarly, betaine hydrochloride's acid-increasing action is directly opposed to that of H2-blockers, which are taken to decrease stomach acid.

Drug Absorption Interactions

Betaine hydrochloride may change the way your body absorbs certain medicines. It may increase or decrease the absorption of various medicines, which can change their effects and side effects in the body. This bidirectional effect — which can either rescue absorption of acid-dependent drugs (e.g., dasatinib, ketoconazole) or interfere with medications whose absorption is adversely affected by increased gastric acidity — makes betaine HCl a clinically relevant pharmacokinetic modifier.

Physical Handling

HCl can irritate sensitive tissue and can be corrosive to teeth; therefore, capsules should NOT be emptied into food or dissolved in beverages.

Pregnancy and Breastfeeding

Not enough is known about the use of betaine hydrochloride during pregnancy and breast-feeding; it is advised to stay on the safe side and avoid use.

Special Populations

Safety for young children, pregnant or nursing women, or those with severe liver or kidney disease has not been established.

Cholesterol Monitoring

A significant increase in total and LDL-cholesterol concentrations was noted at intakes of 4 g/day of betaine in overweight subjects with metabolic syndrome. At typical supplement doses (325–650 mg per meal), this threshold may not be reached, but at high doses used for homocysteine lowering it becomes a documented concern.

Regulatory Status

Betaine HCl products may be sold as dietary supplements; however, products marketed to treat hypochlorhydria/achlorhydria or as OTC stomach acidifiers risk drug-claim territory. The FDA has stated OTC stomach-acidifier products are not generally recognized as safe and effective. It is not FDA-approved for any specific indication — not for hypochlorhydria, not for GERD, not for B12 deficiency.

The European Union has authorized the health claim that betaine "contributes to normal homocysteine metabolism." This claim applies to betaine as a food ingredient, not specifically to betaine HCl as a supplement.

The FDA-approved betaine anhydrous product (Cystadane) is recommended for the treatment of high levels of homocysteine in the urine (homocystinuria), and betaine hydrochloride should not be confused with betaine anhydrous for this purpose.

8. Overall Evidence Assessment

The popular clinical protocol for betaine HCl dose titration has not been rigorously tested in a research setting, though thousands of clinicians follow such recommendations with positive anecdotal outcomes. While some small studies suggest that betaine hydrochloride effectively increases stomach acid, these studies often lack rigorous scientific backing; consequently, its effectiveness for most of the aforementioned conditions remains largely unverified by substantial research.

The most scientifically solid findings for betaine HCl are:

Gastric pH reduction: Demonstrated in small, well-designed human studies (N = 6–8) under drug-induced hypochlorhydria. Effect is rapid (onset ~6 minutes), temporary (duration ~1 hour), and dose-dependent at 1500 mg.
Drug absorption enhancement: In fasted-state conditions, BHCl at 1500 mg reversed PPI-induced impairment of dasatinib absorption in a three-way crossover trial. Effect is context-dependent and food diminishes the re-acidification.
Homocysteine lowering / lipid effects (betaine, not specifically BHCl): Multiple RCTs and meta-analyses demonstrate homocysteine lowering with betaine supplementation at 4–6 g/day, but this is simultaneously accompanied by increases in LDL and total cholesterol. Net cardiovascular benefit is uncertain.

Areas where evidence is absent or very weak include nutrient absorption improvement, allergy reduction, asthma improvement, and all proposed uses related to immune conditions — these remain without controlled clinical data.

References

Health Conditions

Health conditions that HCL may help support.

No conditions available.

Body Systems

Body systems that HCL may help support.

No body systems available.